Daniel R. Rhodes, Ph.D.
Co-Founder & CEO

Dr. Rhodes has an 8-year track record in cancer genomics and informatics with more than 30 papers published in peer-reviewed journals. He received a Ph.D. in Bioinformatics from the University of Michigan, contributing to several important advances in the field, including the seminal discovery of recurrent gene fusions in prostate cancer. Dr. Rhodes led the original development of Oncomine™ and the Oncomine Concepts Map in addition to several novel bioinformatics methods, including Meta-analysis of Microarrays and Cancer Outlier Profile Analysis (COPA). He has received several awards for his work including the Harold Weintraub Award and the Team Science Award from the AACR. Dr. Rhodes also maintains a part-time faculty research position at the University of Michigan Center for Translational Pathology.

Colleen Kincaid-Beal
Chief Operating Officer

Colleen Kincaid-Beal is the Chief Operating Officer with responsibility for project management, quality management, and customer support and vendor management. Ms. Kincaid-Beal oversees internal project teams to ensure progress towards project milestones with appropriate budget and resource management. Ms. Kincaid-Beal's professional experience includes 10 years with a leading clinical data CRO, I3 Statprobe. She served I3 in a variety of roles as clinical data manager, biostatistician and most recently as Sr. Director of Data Management Programming where she held line and project management responsibility for as many thirty staff working on seventy projects. Included in her portfolio of projects was her leadership role in the development, testing, and support of a secure web-based clinical trial management portal that allowed clinical trial sponsors to review data and data processes and conduct real-time online data analysis.

John Freshley
Chief Business Officer

John Freshley is an experienced life-sciences entrepreneur having recently served as President and CEO of Genetics Squared, Inc., an oncology therapeutic development company. In this role, Mr. Freshley led the closure of the Series A financing, recruited a world-class management team with more than 35 years of pharmaceutical industry experience and an industry-leading oncology-focused Scientific Advisory Board. Prior to his term at Genetics Squared, Mr. Freshley served as Director of Corporate Development and Marketing for STATPROBE, a clinical research company. Earlier in his career, Mr. Freshley served in a variety of management roles with operational and business development responsibilities, including Director of Business Development for a start-up cancer discovery and development company and as a founding employee and Director of Marketing for an enterprise software company, Grapevine Technologies, that was sold to Sun Microsystems in 1999.

Peter Wyngaard
VP Product Development

Peter Wyngaard is Vice President of Product Development with responsibilities for overseeing software development, personnel, and contractors. Mr. Wyngaard is responsible for overseeing and guiding software, database, and system design, implementation, integration, and testing. Mr. Wyngaard has extensive experience implementing large-scale, commercial, database-driven web applications. As founder and CEO of a web application development firm, InterConnect, he oversaw a team of 14 developers working on several projects simultaneously. As a software architect and developer, Mr. Wyngaard has experience creating searching and browsing interfaces to multi-terabyte academic research databases, and experience designing and implementing content management systems.

Matt Anstett, MSc
VP Scientific Applications

Matt Anstett has ten years of experience in molecular biology, molecular diagnostics and assay development supporting patient diagnostics and drug discovery. Additionally, during his six years with Spotfire, he made significant contributions through partner collaborations, marketing, customer loyalty, software development and achievement of revenue goals that helped position the company as a leading Life Science informatics company. Mr. Anstett has contributed to a number of journals, industry publications and books on Microarray Analysis and High Content Screening.

Arul Chinnaiyan, M.D., Ph.D.
Co-Founder

Dr. Chinnaiyan is a Professor in the Department of Pathology and Urology at the University of Michigan Medical School. Dr. Chinnaiyan is the Director of Cancer Bioinformatics and the co-Director of the Division of Pathology Informatics. Dr. Chinnaiyan is recognized as a world leader in cancer genomics and has authored more than 100 peer-reviewed publications including in high-impact journals such as Nature, Science, Cell, JAMA and the New England Journal of Medicine. He holds the distinguished S.P. Hicks Endowed Professorship of Pathology and has received numerous awards for his work including the Amgen Outstanding Investigator Award and the Pew Biomedical Scholar Award.